Elizabeth Sugar
Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elizabeth Sugar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07059091 · Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDJohns Hopkins University · recruiting · Chronic Obstructive Pulmonary Disease (COPD), Allergies · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) TrialUG1EY028091 · NEI · JOHNS HOPKINS UNIVERSITY · fiscal years 2018 to 2022 · $972,337 awarded in 2022Same name and institution; not confirmed by an ID
- Core 1: Biostatistics CoreP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2018 to 2020 · $106,630 awarded in 2020Same name and institution; not confirmed by an ID
- Leveraging long-term follow-up in the MUST Trial and Follow-up Study: Remission, Ocular outcomes and Quantifying utility in patients with severe uveitis (MUST-ROQ)R21EY029757 · NEI · JOHNS HOPKINS UNIVERSITY · fiscal years 2019 to 2020 · $206,243 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Clinical trial of omalizumab for allergen sensitized and exposed individuals with COPDU01AI177195 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Nadia N Hansel, Nirupama Putcha · fiscal years 2024 to 2026Named on NCT07059091
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:39 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- 768 citationsRCR 40.5
- Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.J Immunother · 2013461 citationsRCR 11.6
- 409 citationsRCR 15.1
- 355 citationsRCR 15.0
- Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.Nat Cancer · 2021323 citationsRCR 17.0
- 317 citationsRCR 7.1
- A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.Clin Cancer Res · 2012302 citationsRCR 7.3
- 259 citationsRCR 10.7
- 236 citationsRCR 4.7
- The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.Am J Ophthalmol · 2010175 citationsRCR 6.5